BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Billè A, Okiror L, Skanjeti A, Errico L, Arena V, Penna D, Ardissone F, Pelosi E. The prognostic significance of maximum standardized uptake value of primary tumor in surgically treated non-small-cell lung cancer patients: analysis of 413 cases. Clin Lung Cancer 2013;14:149-56. [PMID: 22682667 DOI: 10.1016/j.cllc.2012.04.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Konings R, van Gool MH, Bard MPL, Zwijnenburg A, Titulaer BM, Aukema TS, Valdés Olmos RA, Sikorska K, Klomp HM, Rijna H. Prognostic value of pre-operative glucose-corrected maximum standardized uptake value in patients with non-small cell lung cancer after complete surgical resection and 5-year follow-up. Ann Nucl Med 2016;30:362-8. [DOI: 10.1007/s12149-016-1070-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
2 Miyazawa T, Otsubo K, Sakai H, Kimura H, Chosokabe M, Morikawa K, Furuya N, Marushima H, Kojima K, Mineshita M, Koike J, Saji H. Combining PD-L1 Expression and Standardized Uptake Values in FDG-PET/CT Can Predict Prognosis in Patients With Resectable Non-Small-Cell Lung Cancer. Cancer Control 2021;28:10732748211038314. [PMID: 34384268 DOI: 10.1177/10732748211038314] [Reference Citation Analysis]
3 Liu J, Dong M, Sun X, Li W, Xing L, Yu J. Prognostic Value of 18F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-Analysis. PLoS One. 2016;11:e0146195. [PMID: 26727114 DOI: 10.1371/journal.pone.0146195] [Cited by in Crossref: 67] [Cited by in F6Publishing: 72] [Article Influence: 11.2] [Reference Citation Analysis]
4 Zhang M, Wang D, Sun Q, Pu H, Wang Y, Zhao S, Wang Y, Zhang Q. Prognostic significance of PD-L1 expression and 18F-FDG PET/CT in surgical pulmonary squamous cell carcinoma. Oncotarget 2017;8:51630-40. [PMID: 28881674 DOI: 10.18632/oncotarget.18257] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 7.2] [Reference Citation Analysis]
5 Kerner GS, Fischer A, Koole MJ, Pruim J, Groen HJ. Evaluation of elastix-based propagated align algorithm for VOI- and voxel-based analysis of longitudinal (18)F-FDG PET/CT data from patients with non-small cell lung cancer (NSCLC). EJNMMI Res 2015;5:15. [PMID: 25853021 DOI: 10.1186/s13550-015-0089-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
6 Kurtipek E, Çayci M, Düzgün N, Esme H, Terzi Y, Bakdik S, Aygün MS, Unlü Y, Burnik C, Bekci TT. (18)F-FDG PET/CT mean SUV and metabolic tumor volume for mean survival time in non-small cell lung cancer. Clin Nucl Med 2015;40:459-63. [PMID: 25742234 DOI: 10.1097/RLU.0000000000000740] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
7 Wang Y, Zhao N, Wu Z, Pan N, Shen X, Liu T, Wei F, You J, Xu W, Ren X. New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2020;47:1127-36. [PMID: 31502013 DOI: 10.1007/s00259-019-04500-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
8 Yaprak G, Ozcelik M, Gemici C, Seseogullari O. Pretreatment SUVmax value to predict outcome in patients with stage III NSCLC receiving concurrent chemoradiotherapy. North Clin Istanb 2019;6:129-33. [PMID: 31297478 DOI: 10.14744/nci.2019.02212] [Reference Citation Analysis]
9 Schmidt-Hansen M, Baldwin DR, Hasler E, Zamora J, Abraira V, Roqué I Figuls M. PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer. Cochrane Database Syst Rev 2014;:CD009519. [PMID: 25393718 DOI: 10.1002/14651858.CD009519.pub2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
10 Iommelli F, De Rosa V, Fonti R, Del Vecchio S. Molecular imaging for detection of sensitivity and resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. Clin Transl Imaging 2014;2:43-53. [DOI: 10.1007/s40336-014-0050-6] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
11 Ozmen O, Yilmaz U, Dadali Y, Tatci E, Gokcek A, Aydin E, Okuyucu K, Arslan N. Use of FDG PET/CT in Patients with Pancoast Tumors: Does It Add Any Contribution to Patient Management? Cancer Biother Radiopharm 2015;30:359-67. [PMID: 26367245 DOI: 10.1089/cbr.2014.1809] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
12 Hui Z, Wei F, Ren H, Xu W, Ren X. Primary tumor standardized uptake value (SUVmax) measured on 18F-FDG PET/CT and mixed NSCLC components predict survival in surgical-resected combined small-cell lung cancer. J Cancer Res Clin Oncol 2020;146:2595-605. [PMID: 32494919 DOI: 10.1007/s00432-020-03240-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Chen J, Xia J, Huang J, Xu R. Effect of aspirin on PET parameters in primary non-small cell lung cancer and its relationship with prognosis. BMC Cancer 2020;20:510. [PMID: 32493238 DOI: 10.1186/s12885-020-06983-2] [Reference Citation Analysis]
14 Köhler J, Schuler M, Gauler TC, Nöpel-dünnebacke S, Ahrens M, Hoffmann A, Kasper S, Nensa F, Gomez B, Hahnemann M, Breitenbuecher F, Cheufou D, Özkan F, Darwiche K, Hoiczyk M, Reis H, Welter S, Eberhardt WEE, Eisenacher M, Teschler H, Stamatis G, Schmiegel W, Hahn SA, Baraniskin A. Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients. J Cancer Res Clin Oncol 2016;142:795-805. [DOI: 10.1007/s00432-015-2095-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
15 Ke L, Wang L, Yu J, Meng X. Prognostic Significance of SUVmax Combined With Lactate Dehydrogenase in Advanced Lung Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Retrospective Study. Front Oncol 2021;11:652312. [PMID: 34094942 DOI: 10.3389/fonc.2021.652312] [Reference Citation Analysis]
16 Hennon M, Landreneau RJ. Role of Segmentectomy in Treatment of Early-Stage Non–Small Cell Lung Cancer. Ann Surg Oncol 2018;25:59-63. [DOI: 10.1245/s10434-017-5787-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
17 Ren H, Xu W, You J, Song X, Huang H, Zhao N, Ren X, Zhang X. [Analysis of the Role of PET/CT SUVmax in Prognosis and Its Correlation with 
Clinicopathological Characteristics in Resectable Lung Squamous Cell Carcinoma]. Zhongguo Fei Ai Za Zhi 2016;19:192-9. [PMID: 27118646 DOI: 10.3779/j.issn.1009-3419.2016.04.03] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
18 Zhao K, Wang C, Shi F, Huang Y, Ma L, Li M, Song Y. Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy. BMC Cancer 2021;21:66. [PMID: 33446134 DOI: 10.1186/s12885-021-07784-x] [Reference Citation Analysis]